alexa Management of myocardial ischemia. Is ranolazine needed? For all or some patients with myocardial ischemia?


Cardiovascular Therapy: Open Access

Author(s): GCOCCO

Abstract Share this page

Given the prevalence, high morbidity, mortality and impaired quality of life, ischemic heart disease (IHD) is a major medical challenge. The use of myocardial revascularization techniques and of antianginal and cardioprotective drugs had an outstanding positive therapeutic impact. However, under anatomic circumstances in some patients a complete revascularization may be impossible, for example, after previous interventions or in the presence of peripheral pathology. In some patients conventional antianginal drugs, such as β-blockers, calcium-channel blockers, nicorandil (a nitrate and K+- and ATP-channel agonist), molsidomine and ivabradine either exert reduce symptoms to an insufficient extent or the therapy induces limiting side effects. Last, up to 10% of all patients with angina pectoris (mostly women) have symptoms and cardiac ischemia in the absence of significant coronary artery disease, supposedly because of microcoronary dysfunction.

  • To read the full article Visit
  • Open Access
This article was published in Expert Opinion on Pharmacotherapy and referenced in Cardiovascular Therapy: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version